Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

"Oh the possibilities…"
A reminder of what Richard Scott wrote back in the PYMX heyday

Defensin Mimetics--Using Nature to Keep Us Safer
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61912711

Scott's overview is perhaps the best re what Polymedix had going on. And this coming from someone who knew... knows still.... someone still involved -- a CTIX partner advancing the gram-neg, anti-fungal work at Fox Chase.

Below the former PYMX IP Portfolio that is now CTIX's - an embarrassment of riches
http://www.sec.gov/Archives/edgar/data/1355250/000147793214000933/filename1.htm

The platform is phenomenally-logically (new word) pregnant, loaded, bug-free (take your pick) with upside potential (lives, $ saved).... Brilacidin and analogs as a Next-Gen ABX (resistance as less likely, maybe even futile; good odds on ABSSSI approval); PolyCides (coatings, industrial-material apps); PolyDerm (per what Leo just announced, Skin Products, not Brilacidin but another HDP-mimetic compound as Drano, TOB clarified), PolyDentix (oral candidiasis), Poly(fill in blank), etc.

The science is sound with others now playing a lot of catch-up, still in discovery phases (U of MD, IBM Research Labs and their Ninja Polymers, Ohio State etc). Dipexium Pharma, N8 Medical and the Hancock group (he's a host defense guru of sorts...) out of U of BC farthest along.

U of MD Def Mimetic
http://www.umventures.org/technologies/defensin-molecules-novel-antimicrobial-agents
http://journals.plos.org/plospathogens/article/asset?id=10.1371/journal.ppat.1003732.PDF

IBM Ninja Polymers
http://www.research.ibm.com/featured/ninjas/images/Ninjas-Infographic_12.03.2013.pdf
http://www.research.ibm.com/articles/nanomedicine.shtml#fbid=OMLbUqBG9Rp
http://www.engadget.com/2014/09/11/ibm-ninja-particles-could-stop-superbugs/

Ohio State Research
http://news.osu.edu/news/2015/01/07/the-best-offense-against-bacteria-is-a-good-defense/

Dipexium Pharma/Locilex (maiganin/pexiganin)
http://content.stockpr.com/dipexiumpharmaceuticals/media/69e0f9c3cd2f48e2d6be9565490df032.pdf

N8 Medical (ceragenins) (presenting at ECCMID too)
http://www.n8medical.com/

Hancock / U of BC
http://cmdr.ubc.ca/bobh/research.htm

As A-17 and others have noted, the depth and breadth on the pre/clinical PYMX work amazes, pub'd studies galore.... DeGrado (now at UCSF), Tew (U Mass-Amherst), Scott (Fox Chase), Klein (Temple), Kuroda (U of Mich).... Landekic too.

Degrado: http://pharm.ucsf.edu/degrado/research
Tew: http://www.pse.umass.edu/faculty/researchgroup/tew
Scott: http://www.fc-cdci.com/documents/FCCDC_Service_Offering.pdf
Klein: https://icms.cst.temple.edu
Kuroda: https://sites.google.com/a/umich.edu/kurodalab/research

They were way-Way ahead of the curve in identifying a novel approach to ABX, anti-infectives. (And don’t forget the immunomodulatory -- anti-inflammatory -- even anti-cancer properties per newer research, even anti-viral activity.) U Penn had a perfect blend of Chem-Quant mind wattage to improve upon nature herself via biomimetics, per the Forbes piece on DeGrado (his lightbulb moment... Doodling on a scrap of paper; no surprise he's this year's winner of the Protein Society's equivalent of a Nobel) and the Klein SuperComputing backstory, and the Landekic interviews, all linked to below.

Forbes: The Genius Chemist and His Assault on Mutant Killer Bacteria
http://www.forbes.com/sites/robertlangreth/2011/01/28/the-genius-chemist-and-his-assault-on-mutant-killer-bacteria/

Biomemetic/Supercomputing Backstory
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110453925

Landekic Interviews
http://www.twst.com/interview/16845
http://www.sec.gov/Archives/edgar/data/1341843/000089322007002893/w38545exv99w1.htm

That Leo and Menon stalked PYMX and got it, with the help of their sons (rumor has it), all those assets, all for a few $ million plus equity -- smart and lucky, and benefiting from Big Pharma bureaucracy undoubtedly. Recall they maintain rights to the U Penn uber-software program so it will be interesting to see what might be "rationally designed" (as they say) next. I'm hoping CTIX brings on more of the former PYMXers (Jorgensen and the other guy, patient recruitment/site coordinator), from among those ref'd above, back into the fold in some way (say as clinical advisors).

(A-17, A-vakra, rr50: That study I posted yesterday was interesting and I think goes to show how the HDP-M platform of compounds can be tweaked, modified... Think anti-malarial, anti-TB etc. The lead oligomer they ref'd one would think might have been the precursor for Brilacidin if not it. I also think the patents protect their particular mimetic approach but a patent lawyer I am not... Remember though the researchers filing patent for their antimicrobial compound for sutures had to admit -- footnote -- another prior Polymedix claim, per the Tew triclosan study.)

Anyway, I know there are those who think some of us IHUBers have been sipping generously, deliriously, group-hugging from a Brilacidin-flavored jug of Kool-Aid... Although it has arguably been a drunkfest with good reason:

ABX Resistance as potentially Futile
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111223232

Good Approval Odds (for ABSSSI)
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110335346

Each/Own... But imho if you really understand what PYMX had (backed by real - and pub'd - science done by brilliant scientists, waylaid due to the PMX-60056 fubar) and what CTIX is following thru on, I can't see how patients and investors can't get JAZZed, PCYCed. Nothing is ever guaranteed, but I like the chances.....

Then there is Prurisol (a lower priority of late it seems) and esp Kevetrin. K holds even more potential than the HDP-Mimetics. The Dana Farber news release (whatever form it takes) will help asses the hype/hope/"hurry-up-and-get-here-already" ratio.

Good times ahead. Can't wait for more substantive updates that have been queuing.

Personally I'm banking on Brilacidin, betting on Kevetrin -- with Prurisol bonus.